9 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 12 Phase 2, 7 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 6, Terminated 3, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 4, Terminated 2, Withdrawn 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow BL-8040: new trials by email Literature Review of BL-8040 trials Research Report on BL-8040
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization Motixafortide, G-CSF - Multiple Myeloma | Phase 1 | Completed | Washington University School of Medicine | 20 | 2024-10-31 | 2025-08-29 |
| Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) Motixafortide, Natalizumab, Leukapheresis - Sickle Cell Disease | Phase 1 | Completed | Washington University School of Medicine | 10 | 2023-07-07 | 2025-08-11 |
| Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma Motixafortide, Cemiplimab, Gemcitabine - Pancreatic Cancer, Adenocarcinoma of the Pancreas | Phase 2 | Active not recruiting | Columbia University | 118 | 2020-11-09 | 2026-09-21 |
| Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) BL-8040, Atezolizumab - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | BioLineRx, Ltd. | 1 | 2018-01-08 | 2024-09-05 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin - Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 219 | 2017-10-13 | 2026-08-03 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Nab-Paclitaxel, Gemcitabine, Oxaliplatin - Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 341 | 2017-07-05 | 2025-11-21 |
| BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma BL-8040, Nelarabine - T-Acute Lymphoblastic Leukemia, Adult T Lymphoblastic Lymphoma | Phase 2 | Terminated | Washington University School of Medicine | 12 | 2016-12-02 | 2023-10-31 |
| Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer CXCR4 Antagonist BL-8040, Pembrolizumab, Pharmacological Study - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2016-12-01 | 2025-02-19 |
| Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients BL-8040, Pembrolizumab, Chemotherapy - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Completed | BioLineRx, Ltd. | 80 | 2016-09-01 | 2024-08-28 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies BL-8040, Leukapheresis, Hematopoietic cell transplant - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Washington University School of Medicine | 50 | 2016-03-31 | 2023-11-07 |
| Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome BL-8040, horse anti-thymocyte globulin (hATG), Methylprednisolone - Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome | Phase 2 | Completed | BioLineRx, Ltd. | 11 | 2015-10-01 | 2020-12-29 |
| BL-8040 Addition to Consolidation Therapy in AML Patients Cytarabine, BL-8040, Placebo (for BL-8040) - Acute Myeloid Leukemia | Phase 2 | Unknown | Dr. Petra Tschanter | 194 | 2015-09-01 | 2015-09-21 |
| Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia BL-8040 - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Sheba Medical Center | 2014-11-01 | 2016-08-15 | |
| A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers BL-8040, Placebo - Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB) | Phase 1 | Completed | BioLineRx, Ltd. | 33 | 2014-08-01 | 2015-07-31 |
| Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients Ara-C, BL-8040 - Acute Myeloid Leukemia | Phase 2 | Completed | BioLineRx, Ltd. | 42 | 2013-04-01 | 2024-09-19 |
Leukemia, Myeloid, Acute (4) · Multiple Myeloma (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Adenocarcinoma (1) · Anemia, Aplastic (1) · Anemia, Sickle Cell (1) · Esophageal Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Pancreatic Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
BioLineRx, Ltd. (5) · Washington University School of Medicine (4) · Hoffmann-La Roche (2) · Columbia University (1) · Dr. Petra Tschanter (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · Sheba Medical Center (1)
United States (13) · Israel (6) · Spain (4) · South Korea (3) · Germany (2) · Australia (1) · Czechia (1) · Japan (1) · Poland (1) · Slovakia (1) · Taiwan (1) · United Kingdom (1)
Arnon Aharon, MD (2) · Zachary Crees, M.D. (2) · Abi Vainstein, MD (1) · Arnon Nagler, MD (1) · Brandon G. Smaglo, MD (1) · Geoffrey L Uy, M.D. (1) · Geoffrey Uy, M.D. (1) · Gulam Manji, MD,PhD (1) · Joseph Rimando, MD (1) · Tapan Kadia, MD (1)
PMID 36940261, PMID 32451495, PMID 39707623, PMID 41449151, PMID 41980027, PMID 42811017
2016 (2), P30CA138292 (1), P50CA171963 (1)